Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?

Core Insights - Voyager Therapeutics (VYGR) shares experienced an 11.6% increase, closing at $5.28, with trading volume higher than average, contributing to an 18.1% gain over the past four weeks [1][2] Company Overview - The surge in VYGR's stock price is attributed to increasing investor optimism regarding its clinical candidate VY7523 (anti-tau antibody), which is in early-stage development for Alzheimer's disease [2] - Voyager Therapeutics is projected to report a quarterly loss of $0.53 per share, reflecting a year-over-year decline of 231.3%, with expected revenues of $8.51 million, down 65.4% from the previous year [2] Earnings and Revenue Expectations - The consensus EPS estimate for Voyager Therapeutics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Voyager Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, alongside Alvotech (ALVO), which saw a 0.5% increase to $8.68 and has returned 6.5% over the past month [4] - Alvotech's consensus EPS estimate for its upcoming report is $0.08, representing a 57.9% decline from the previous year, and it also holds a Zacks Rank of 3 (Hold) [5]